Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia Recognized For Disrupting Healthcare Diagnostics By CB Insights

By Proscia | January 13, 2021

The COVID-19 pandemic has cast a spotlight on diagnostics. From a seemingly never-ending reel of stories on the news to our own experiences getting tested, the global pandemic has made laboratory medicine especially top of mind. And as we’ve had to adapt to the new normal, it’s also opened up opportunities for organizations to disrupt the traditional diagnostics model. 

So it’s hardly surprising that CB Insights, a leading market intelligence firm on private, high-growth companies, recently took a deep dive into the organizations unbundling traditional healthcare testing. CB Insights notes that pathology, with an emphasis on pattern recognition and massive amounts of data, is an area ripe for change with AI and calls out Proscia as a key player in driving its digital transformation. 

Importantly, realizing this promise – and accelerating pathology’s shift away from a microscope-based standard of care – requires combining enterprise scalability with powerful AI applications. We are proud to be the only company on the list delivering on this approach. With our AI-enabled Concentriq platform, we’re making it possible to drive powerful efficiencies, unlock new insights, and ultimately improve patient outcomes, helping laboratories to go beyond the limits of the human sight to keep pace with the rising diagnostic burden.

You can view CB Insights’ full report here

Our website uses cookies. By using this site, you agree to its use of cookies.